Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

The comparison trial evaluated 751 adults with obesity or overweight (no diabetes) over 72 weeks. According to published data, participants taking Zepbound (tirzepatide) lost an average of 20.2% of ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...